Subscribe
shutterstock_1928703866_bukhta_yurii
Bukhta Yurii / Shutterstock.com
3 August 2023FeaturesBig PharmaPriscila Kashiwabara and Luan Scalzitti

Cannabis and IP: Nurturing innovation in Brazil’s life sciences industry

The cannabis industry has experienced increasing recognition, mainly due to its versatile applications. Due to the pharmaceutical properties of medical cannabis (or medical marijuana), many countries have legalised its use.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Plant Varieties
Haynes Boone launches CBD advisory practice
8 September 2021   International law firm Haynes Boone has launched the CBD Hemp Industry Group to advise businesses on the burgeoning cannabinoid market.
Plant Varieties
New York judge denies arbitration request in $881m cannabinoid suit
27 July 2021   A New York federal court has denied biotechnology company Amyris’ bid for arbitration in an $881 million trade secrets and patent infringement dispute with cannabis firm Lavvan.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

To disclose or not: Pharma patents face new AI reality
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Trump’s march-in rights threat: Why pharma is rethinking collaborations
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space